Abstract:Pd1 and Pd2 selectively decrease the viability of cancer cells via cell cycle arrest and activation of caspase‐dependent mitochondrial apoptotic pathway. Binuclear [{Pd (dien)}2(μ‐pz)](ClO4)4 (Pd1) and [{Pd (dien)}2(μ‐pydz)](ClO4)4 (Pd2) complexes, where pz is 1,4‐diazine and pydz is 1,2‐diazine bridging ligands and dien (diethylenetriamine) is a tridentately coordinated triamine ligand, were synthesized and characterized using elemental analysis, NMR (1H and 13C) spectroscopy, and UV–Vis spectrophotometry. Electronic absorption spectrophotometry and fluorescence spectroscopy were used to study the interactions of the prepared Pd1 and Pd2 complexes with deoxyribonucleic acid (CT‐DNA) and bovine serum albumin (BSA). According to the UV–Vis spectrophotometric data, the complexes interact with CT‐DNA and bind to the BSA as a possible carrier to the target site. The antitumor properties of the tested palladium compounds were evaluated on three types of human cancer cells, namely, squamous cell carcinoma cells SCC‐4, cervical carcinoma cells HeLa and colorectal carcinoma cells HCT116, and one type of malignantly unchanged cells, MRC‐5 fibroblasts. The highest cytotoxicity was shown by the Pd1 compound against SCC‐4 cell, with an IC50 value of 5.4 ± 1.2 μM. The results showed that the cytotoxic potential against SCC‐4 cells of our new palladium complexes Pd1 and Pd2 was comparable with the cytotoxic potential of cisplatin and oxaliplatin. However, Pd1 and Pd2 displayed significantly lower cytotoxicity in comparison with cisplatin and oxaliplatin against non‐malignant cells, fibroblasts MRC5, so these results may suggest that local and systemic complications of antitumor therapy could be reduced and/or avoided. Both compounds selectively decreased the viability of SCC‐4 cells by induction of apoptosis. Also, Pd1 and Pd2 induced S‐phase cell cycle arrest in human SCC‐4 cells, so that could be another mechanism to halt the uncontrolled growth and division of cancer cells. Moreover, the precise molecular mechanism of Pd1 and Pd2 complexes‐induced apoptosis was the activation of the intrinsic signaling pathway of apoptosis, which also included activation of caspase‐3. Therefore, our new palladium (II) complexes might have a promising role as the potential future cytostatic agents.

Palladium complexes with terpene derivatives of ethylenediamine and benzylamine: Synthesis and study of antitumor properties

Palladium(II) Complexes with N,N′-Dialkyl-1,10-phenanthroline-2,9-dimathanamine: Synthesis, Characterization and Cytotoxic Activity

Biologically Active Palladium(II), Zinc(II), and Copper(II) Complexes with Terpene Ligands as Potential Pharmaceutical Drugs

Synthesis, characterization and anticancer properties: A series of highly selective palladium(II) substituted-terpyridine complexes

Mixed N‐heterocyclic carbene and benzyl‐, phenethyl‐, and biphenylamine coordinated Pd complexes: Anticancer activities and stereo‐electronic effects

Rational Design of Palladium(II) Indenyl and Allyl Complexes Bearing Phosphine and Isocyanide Ancillary Ligands with Promising Antitumor Activity

Palladium(II)‐Imidoyl Complexes: A New Piece in the Puzzle of Organopalladium Anticancer Agents

Synthesis, characterisation, and anticancer and antioxidant activities of novel complexes of palladium and an organic Schiff-base ligand

Platinum and Palladium Polyamine Complexes as Anticancer Agents: The Structural Factor

Cytotoxic palladium(II) complexes of 8-aminoquinoline derivatives and the interaction with human serum albumin.

Synthesis, characterization, and biomedical evaluation of ethylene-bridged tetra-NHC Pd(II), Pt(II) and Au(III) complexes, with apoptosis-inducing properties in cisplatin-resistant neuroblastoma cells

Pd(ii) complexes bearing NNS pincer ligands: unveiling potent cytotoxicity against breast and pancreatic cancer

The cytotoxicity of palladium (II) complexes containing 1,2‐ or 1,4‐diazine bridging ligands on squamous cell carcinoma cells in vitro: Insights in the mechanisms of action

Synthesis and Anticancer Properties of Heterobimetallic Fe(II)/Pd(II) Complexes Bearing Different Butadienyl Fragments

Anticancer and antimicrobial properties of novel η6- p-cymene ruthenium(ii) complexes containing a N,S-type ligand, their structural and theoretical characterization

Synthesis and Antitumor Activity of Dinuclear Platinum Complexes with (1(i)R, 1(ii)R, 2(i)R, 2(ii)R)-N-i,N-ii-(1, 3-Phenylenebis(methylene))dicyclohexane-1, 2-diamie as the Ligand

New sugar-incorporated N-heterocyclic carbene precursors and their Ag(I) and Pd(II) complexes: Synthesis, characterization, and cytotoxicity studies

Synthesis and anticancer activities of novel Pt (II) and Pd (II) complexes with 4‐(2,2′:6′,2′′‐terpyridin‐4′‐yl)phenol as ligand

Potent saccharinate-containing palladium(II) complexes for sensitization to cancer therapy

Anticancer behaviour of 2,2′-(pyridin-2-ylmethylene)bis(5,5-dimethylcyclohexane-1,3-dione)-based palladium(II) complex and its DNA, BSA binding propensity and DFT study

Synthesis, characterization, DNA/BSA-binding affinity and biological activity of dinuclear palladium(II) complexes with aromatic N-heterocyclic bridging ligand